CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
We are very excited to launch our new website! Please take a few moments to click around and explore...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...